X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs VENUS REMEDIES - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH VENUS REMEDIES STERLING BIOTECH/
VENUS REMEDIES
 
P/E (TTM) x -0.4 -3.6 - View Chart
P/BV x 0.0 0.1 10.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 STERLING BIOTECH   VENUS REMEDIES
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
VENUS REMEDIES
Mar-18
STERLING BIOTECH/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs11126 8.3%   
Low Rs361 5.6%   
Sales per share (Unadj.) Rs26.8301.8 8.9%  
Earnings per share (Unadj.) Rs-15.0-24.9 60.1%  
Cash flow per share (Unadj.) Rs-5.52.5 -214.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs54.9293.3 18.7%  
Shares outstanding (eoy) m267.8712.34 2,170.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.3 83.7%   
Avg P/E ratio x-0.5-3.8 12.4%  
P/CF ratio (eoy) x-1.336.7 -3.5%  
Price / Book Value ratio x0.10.3 39.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,8621,154 161.4%   
No. of employees `0001.40.9 146.4%   
Total wages/salary Rs m547393 139.1%   
Avg. sales/employee Rs Th5,303.34,026.1 131.7%   
Avg. wages/employee Rs Th403.8425.0 95.0%   
Avg. net profit/employee Rs Th-2,959.0-331.8 891.8%   
INCOME DATA
Net Sales Rs m7,1813,724 192.8%  
Other income Rs m4323 189.3%   
Total revenues Rs m7,2233,747 192.8%   
Gross profit Rs m947395 239.8%  
Depreciation Rs m2,543338 751.8%   
Interest Rs m4,377354 1,235.4%   
Profit before tax Rs m-5,931-275 2,154.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,92432 -6,089.6%   
Profit after tax Rs m-4,007-307 1,305.5%  
Gross profit margin %13.210.6 124.4%  
Effective tax rate %32.4-11.5 -282.7%   
Net profit margin %-55.8-8.2 677.1%  
BALANCE SHEET DATA
Current assets Rs m14,3352,638 543.5%   
Current liabilities Rs m49,8092,305 2,161.2%   
Net working cap to sales %-494.08.9 -5,524.4%  
Current ratio x0.31.1 25.1%  
Inventory Days Days403135 297.9%  
Debtors Days Days17146 368.3%  
Net fixed assets Rs m55,4324,871 1,138.1%   
Share capital Rs m268123 217.1%   
"Free" reserves Rs m13,9353,496 398.6%   
Net worth Rs m14,7013,619 406.2%   
Long term debt Rs m9,4781,374 689.6%   
Total assets Rs m73,9887,509 985.4%  
Interest coverage x-0.40.2 -159.2%   
Debt to equity ratio x0.60.4 169.8%  
Sales to assets ratio x0.10.5 19.6%   
Return on assets %0.50.6 79.3%  
Return on equity %-27.3-8.5 321.4%  
Return on capital %-6.41.6 -406.2%  
Exports to sales %25.90-   
Imports to sales %0.213.9 1.2%   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12517 2.4%   
Fx inflow Rs m1,8600-   
Fx outflow Rs m25517 4.8%   
Net fx Rs m1,835-517 -355.3%   
CASH FLOW
From Operations Rs m1,719514 334.1%  
From Investments Rs m-3,148-123 2,557.4%  
From Financial Activity Rs m1,426-387 -368.4%  
Net Cashflow Rs m-34 -81.0%  

Share Holding

Indian Promoters % 33.9 32.9 103.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.2 -  
FIIs % 9.9 0.6 1,706.9%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 66.4 59.2%  
Shareholders   21,482 20,121 106.8%  
Pledged promoter(s) holding % 55.9 36.4 153.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  NATCO PHARMA  BIOCON LTD  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 8-QTR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS